Press "Enter" to skip to content

High-cost Gilead cell therapy proves durable for some lymphoma patients

Nearly 40 percent of lymphoma patients treated with a single infusion of Gilead Sciences Inc’s Yescarta were still responding to the cell therapy after at least two years of follow-up, the company said on Sunday.

Original source:

Also Read:   Bristol-Myers defends Celgene bet as investor criticism grows